Osavampator (TAK-653, NBI-1065845) is a positive allosteric modulator (PAM) of AMPA receptors. It enhances glutamate-induced calcium influx in CHO cells expressing human AMPA receptors with an EC50 of 3.3 µM and potentiates AMPA receptor-mediated currents in rat primary hippocampal neurons with an EC50 of 4.4 µM.

FEN1-IN-1 (Compound 1) is an inhibitor of Flap endonuclease 1 (FEN1), binding to its active site and inhibiting activity partly by coordinating with Mg²⁺ ions. By blocking FEN1, it initiates a DNA damage response, activating the ATM checkpoint pathway, histone H2AX phosphorylation, and FANCD2 ubiquitination in mammalian cells.

FEN1-IN-1 (Compound 1) is an inhibitor of Flap endonuclease 1 (FEN1), binding to its active site and inhibiting activity partly by coordinating with Mg²⁺ ions. By blocking FEN1, it initiates a DNA damage response, activating the ATM checkpoint pathway, histone H2AX phosphorylation, and FANCD2 ubiquitination in mammalian cells.

FEN1-IN-1 (Compound 1) is an inhibitor of Flap endonuclease 1 (FEN1), binding to its active site and inhibiting activity partly by coordinating with Mg²⁺ ions. By blocking FEN1, it initiates a DNA damage response, activating the ATM checkpoint pathway, histone H2AX phosphorylation, and FANCD2 ubiquitination in mammalian cells.

FEN1-IN-1 (Compound 1) is an inhibitor of Flap endonuclease 1 (FEN1), binding to its active site and inhibiting activity partly by coordinating with Mg²⁺ ions. By blocking FEN1, it initiates a DNA damage response, activating the ATM checkpoint pathway, histone H2AX phosphorylation, and FANCD2 ubiquitination in mammalian cells.

AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models.

AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models.

AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models.

Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.

AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models.